menu
    • menu

    Company profile for Servier

    European CDMO and Gx manufacturer with 75 years of experience in delivering premium APIs to pharmaceutical partners worldwide.

    Virtual Booth

    Contact Supplier

    Granules India Limited has high volume world-class facilities for APIs, PFIs, & FDFs, serving customers in over 80 countries.

    Virtual Booth

    Contact Supplier

    Transo-Pharm GmbH works globally to supply Active Pharmaceutical Ingredients adhering to the highest quality & GMP standards.

    Virtual Booth

    Contact Supplier

    TAPI, a leading global supplier of APIs, provides over 350 products and customized CDMO solutions for every stage of development.

    Virtual Booth

    Contact Supplier

    AbbVie CDMO has been working with global companies to develop, manufacture & scale biopharmaceutical products.

    Virtual Booth

    Contact Supplier

    pharmacompass-2-m-2025-10-20

    Virtual Booth

    Contact Supplier

    EVENTS

    DIGITAL CONTENT

    ACTIVE PHARMA INGREDIENTS

    DEVELOPMENTS

    FINISHED DOSAGE FORMULATIONS

    SERVICES

    INSPECTIONS & REGISTRATIONS

    PharmaCompass

    Only Regulatory Products (API/FDF), Drugs in Developments and News are Updated on this Virtual Booth

    Update your Virtual Booth on PharmaCompass, ask us

    About

    Servier is the leading French independent pharmaceutical company, present in 146 countries with over 21 400 employees and a turnover for 2014 of 4 billion euros. 25% of Servier’s annual turnover is reinvested in Research & Development, reflecting the company’s dedication to its research mission of innovation and discovery to treat unmet medical needs. There are no shareholders, and no dividends are distributed from Ser...
    Servier is the leading French independent pharmaceutical company, present in 146 countries with over 21 400 employees and a turnover for 2014 of 4 billion euros. 25% of Servier’s annual turnover is reinvested in Research & Development, reflecting the company’s dedication to its research mission of innovation and discovery to treat unmet medical needs. There are no shareholders, and no dividends are distributed from Servier’s turnover. The main therapeutic areas for which Servier’s research is renowned are oncology, cardiology, metabolism, neuropsychiatry and rheumatology.

    List your booth number for exhibitions, ask us

    CONTACT DETAILS

    Click the arrow to open the dropdown
    Contact SupplierContact
    Google MapGoogle Map
    Full View ScreenFull View Screen
    ServierFrance Flag
    Country
    Country
    France
    Address
    Address
    50 rue Carnot Suresnes, 92150
    Telephone
    Telephone
    +33 1 55 72 60 00
    Client Email
    Email
    enquiries@pharmacompass.com
    Client Website
    Website
    https://servier.com/en/
    Linkedin
    Linkedin
    https://www.linkedin.com/company/servier
    youtube
    YouTube
    Twitter
    Twitter
    https://x.com/servier

    Upload your Marketing & Sales content on your company Virtual Booth, click HERE.

    Events

    Webinars & Exhibitions

    Request a meetingRequest a meeting
    Full Screen ViewFull Screen View
    Default Event

    CPhI WW Frankfurt

    Not Confirmed

    envelop Contact Supplier

    CPhI WW Frankfurt

    Post an Enquiry

    Meeting

    Digital content

    Create Content with PharmaCompass, ask us

    INTERVIEW #SpeakPharma

    [Sponsored by another company]
    “We are building capabilities to stay ahead of the curve, and align with future needs of global healthcare”

    mic“We are building capabilities to stay ahead of the curve, and align with future needs of global healthcare”

    This week, SpeakPharma interviews Girish Chovatia, Chairman and Managing Director of Ami Lifesciences. Since its inception in 2006, Ami Lifesciences has emerged as one of the fastest-growing API manufacturers from India, delivering high-quality active pharmaceutical ingredients (APIs) to global partners across more than 60 countries. With a portfolio of 80+ APIs and strong regulatory accreditations, including those from the US Food and Drug Administration (FDA), European Directorate for the Quality of Medicines & HealthCare (EDQM), and the Pharmaceuticals and Medical Devices Agency (PMDA), the company has built a reputation for innovation, reliability, and customer-centricity.Ami Lifesciences’ ability to combine chemistry expertise with forward-looking strategies such as backward integration, custom synthesis, and a growing focus on platform technologies for next-generation therapeutics sets it apart. The company’s state-of-the-art infrastructure, emphasis on regulatory compliance, and quality culture built from the development stage enable it to serve as a trusted partner to leading pharmaceutical companies worldwide.In this interview, Mr. Girish Chovatia shares key milestones in Ami Lifesciences’ growth journey, its approach to sustainability and innovation, and vision for expanding into new therapeutic areas and technologies to strengthen their global presence.Ami Lifesciences has grown rapidly since it began API operations in 2006. What have been the key strategic decisions or turning points that have fueled this growth?When we started API operations in 2006, we knew we were entering a highly competitive, globalized market. The key turning points in our journey were rooted in making bold but carefully thought-out strategic decisions. The first was building a quality-first culture from day one. We invested early in strong regulatory systems, which allowed us to secure approvals from agencies like FDA, EDQM and, PMDA, opening global markets.Another major factor was our focus on complex chemistry and high-barrier molecules. Instead of competing only in crowded, generic APIs, we decided to differentiate ourselves by developing technically challenging products where our chemistry expertise could shine.We also expanded our global footprint quickly, entering over 60 countries with a diverse product portfolio. Partnerships with leading pharmaceutical companies gave us both credibility and growth momentum. Each milestone—from our first CEP approval to our first FDA clearance—strengthened our foundation.Most importantly, we built a team that believes in long-term value creation, not shortcuts. That culture of quality, innovation, and customer trust continues to fuel our growth.HIGHLIGHTS// Building quality-first culture/focus on complex chemistry/expanding global footprint/belief in long-term value creationWith 80 APIs and a presence in more than 60 countries, how does Ami Lifesciences ensure regulatory compliance and maintain quality standards across such a diverse global footprint?For us, regulatory compliance is not just a requirement—it is the backbone of our credibility. We’ve built a quality culture that starts from the development stage itself. Our dedicated DQA (Development Quality Assurance) and DRA (Development Regulatory Affairs) teams are involved right from early R&D, ensuring that every molecule is designed with regulatory expectations in mind.All our facilities operate under stringent cGMP (current good manufacturing practices) conditions and are routinely audited by leading authorities, including the FDA, EDQM, PMDA, and multiple global partners. We have built robust systems for documentation, training, and monitoring that keep compliance non-negotiable.Equally important is the mindset—we train our teams to think “compliance-first” in every activity, big or small. Whether it’s a lab scientist, a production engineer, or a QA associate, everyone knows that quality and compliance are paramount.This integration of systems, people and, culture ensures that no matter which market we serve—be it the US, Europe, Japan, or emerging economies—our partners receive products of consistently high standards.HIGHLIGHTS// Compliance backbone of credibility/stringent cGMP conditions/‘compliance-first mindset’/consistency in high standardsHow does Ami Lifesciences’ backward integration across key molecules strengthen cost competitiveness and supply chain assurance for its global clients?Backward integration has been a conscious strategy for us. In today’s environment, customers not only seek high-quality APIs but also security of supply and cost competitiveness. By investing in in-house development and manufacture of key intermediates, we reduce dependency on external vendors and volatile supply chains.This gives us multiple advantages. First, it brings down costs and improves pricing stability, making us a more competitive partner globally. Second, it gives us greater control over timelines—something our clients value tremendously, especially in regulated markets. And third, it ensures resilience; even during global disruptions. We can assure our partners of uninterrupted supply.In a market where reliability is as critical as cost, our backward integration strategy has become a cornerstone of trust and long-term partnerships.HIGHLIGHTS// Backward integration strategy/focus on in-house development/lower costs/control over timelines global footprint/resilience during disruptionsHow is Ami Lifesciences leveraging R&D capabilities and custom synthesis to drive innovation in various therapeutic areas? Our R&D strength has always been at the core of our differentiation. We have over 150 scientists dedicated to developing APIs across complex therapeutic areas such as cardiovascular, anti-diabetic, and central nervous system (CNS) disorders.What sets us apart is our ability to go beyond standard generics. We focus on process innovation—green chemistry, enzymatic applications, and continuous improvement—to make synthesis routes not only cost-effective but also environmentally responsible.Custom synthesis is another pillar. Many of our global partners approach us for tailor-made solutions—whether it’s a new intermediate, a complex chiral molecule, or a high-barrier API. Our flexible R&D infrastructure allows us to design and scale processes efficiently, from grams in the lab to multi-ton manufacturing.By marrying strong chemistry capabilities with customer collaboration, we’ve positioned ourselves as more than a manufacturer—we’re an innovation partner contributing to faster, safer, and more affordable therapies worldwide.HIGHLIGHTS// Strong R&D capabilities/complex therapeutic expertise/green chemistry/custom synthesis solutions/innovation partner for safer therapiesWhat are the next big milestones Ami Lifesciences is targeting in terms of product development and global expansion?Looking ahead, we see the future of Ami Lifesciences in both depth and diversification. On the product side, we are expanding into next-generation therapeutics—with focus areas including oncology APIs, ADC payloads and linkers, short peptides, and select biotechnology platforms. These are high-value, high-science areas where our chemistry expertise and process innovation can create significant impact.We are also investing in platform technologies that can be applied across multiple therapeutic areas, giving us a strategic edge in next-gen molecules.From a global perspective, our milestones include broadening our presence in regulated markets like the US, Europe, and Japan, while simultaneously strengthening our reach in fast-growing markets across Asia, LATAM, and Africa.Our guiding principle is to stay ahead of the curve—building a portfolio and capabilities that align with where global healthcare is heading, not just where it is today.HIGHLIGHTS// Expanding to new-gen therapeutics/investing in platform technologies/broadening presence in regulated markets/staying ahead of the curveCould you elaborate on Ami Lifesciences’ ESG initiatives and how they are integrated into your manufacturing and business strategy?Sustainability is no longer optional—it’s integral to how we do business. At Ami, we’ve made ESG a central pillar of our growth strategy.On the environmental front, we are pioneers in integrating green chemistry and enzymatic applications into our processes. By leveraging biocatalysis, we reduce reliance on harsh chemicals, improve atom economy, and minimize energy usage. Our plants are designed for solvent recovery, water recycling, and energy efficiency, with strong commitments to waste reduction and zero liquid discharge.Socially, we invest heavily in our people and communities. From training and development to ensuring a safe workplace, we believe our people are our greatest asset. Beyond our facilities, we engage in education, healthcare, and environmental initiatives that uplift surrounding communities.On governance, we run with transparency, accountability, and ethics at the forefront. Our systems ensure compliance not just with laws but with global best practices in corporate responsibility.This holistic ESG framework ensures that as we grow, we do so responsibly create value for customers, employees, communities, and the environment alike.HIGHLIGHTS// ESG central to growth strategy/energy and resource efficiency/waste reduction and zero liquid discharge/holistic responsible growthHow does Ami Lifesciences’ manufacturing infrastructure enhance scalability and quality for its clients?Our manufacturing infrastructure is built for both flexibility and scale. Our Karakhadi facility (in Gujarat) is approved by leading agencies such as FDA, EDQM, ANVISA (Brazilian Health Regulatory Agency), NMPA (National Medical Products Administration of China) and KMFDS (Korean Ministry of Food and Drug Safety).Our products are filed in many other regulatory agencies like PMDA, NMPA, Therapeutic Goods Administration and Health Canada; giving our partners complete confidence in compliance and quality.The facility has multi-purpose production blocks, allowing us to handle diverse chemistries and scale projects seamlessly—from grams in the lab to multi-ton commercial quantities. This scalability is a key advantage for customers looking for a partner that can support them across the product lifecycle.We further strengthen supply reliability through backward integration of intermediates, which secures both cost efficiency and supply assurance.What makes us unique is the way we integrate quality and sustainability into manufacturing. By embedding quality from the development stage and incorporating green chemistry and enzymatic processes, we ensure that our output is not only reliable and compliant but also environmentally responsible.This combination of regulatory strength, scalability, and sustainable practices makes Ami a trusted long-term partner for leading pharma companies worldwide.HIGHLIGHTS// Flexible, scalable manufacturing infrastructure/facility approved by leading regulators/multi-purpose production blocks/quality, sustainability integrated into manufacturing 

    Impressions: 3142

    subscribeSubscribe

    https://www.pharmacompass.com/speak-pharma/we-are-building-capabilities-to-stay-ahead-of-the-curve-and-align-with-future-needs-of-global-healthcare

    PharmaCompass
    13 Oct 2025
    Share info Share

    VLOG #PharmaReel

    [Sponsored by another company]

    ReelPharmaPartner in End-to-End API ManufacturingPartner in End-to-End API Manufacturing

    Partner in End-to-End API Manufacturing
    Partner in End-to-End API Manufacturing

    reelPartner in End-to-End API Manufacturing

    This PharmaReel showcases Coral Drugs, a global partner in end-to-end API manufacturing with more than 27 years of expertise. Supported by vertically integrated cGMP and ISO-compliant facilities, the company is backed by USFDA and EMA certifications, patents, and advanced micronization capabilities.

    Impressions: 2728

    read-more

    DATA COMPILATION #PharmaFlow

    [Sponsored by another company]
    CDMO Activity Tracker: Veranova, ChemExpress invest in ADC facilities; Cohance to set up oligonucleotide facility in India

    CDMO Activity Tracker: Veranova, ChemExpress invest in ADC facilities; Cohance to set up oligonucleotide facility in India

    The contract development and manufacturing organization (CDMO) sector has emerged as a key partner in new drug development. This was evident from the strategic investments, partnerships, and expansions witnessed in the third quarter (Q3) of 2025. Several CDMOs, such as Cohance Lifesciences, Fermion Oy, Axplora, AGC Pharma Chemicals invested in new projects. Others, including Veranova, Aenova, and Biosynth, expanded capacities, while Ofichem strengthened its footprint with the acquisition of Avivia BV. CDMOs like Fareva, Evonik, and Samsung Biologics forged strategic partnerships for growth. During Q3, the sector continued to adopt artificial intelligence (AI). This prompted the US Food and Drug Administration (FDA) to issue guidance that recognizes the increasing use of AI and data analytics in drug development.  View CDMO Activity Tracker for Q3 2025 (Free Excel Available) Cohance, Veranova invest in bioconjugation suites in US; ChemExpress inks ADC deal Earlier this year, Indian drugmaker Suven Pharmaceuticals Limited merged with  leading CDMO Cohance Lifesciences Limited. The merged entity — Cohance Lifesciences — has invested US$ 10 million in a current Good Manufacturing Practice (cGMP) bioconjugation suite at its subsidiary NJ Bio in Princeton, New Jersey.  NJ Bio is executing a major program for an existing innovator client with multiple antibody-drug conjugate (ADC) candidates. Cohance also announced an INR 230 million (approximately US$ 2.58 million) investment in a cGMP oligonucleotide facility at its Hyderabad (India) site. Veranova’s Devens (Massachusetts) site successfully passed a routine FDA cGMP surveillance inspection with a “No Action Indicated” (NAI) classification. Earlier, the company had initiated a US$ 50 million investment to expand its ADC and bioconjugate capabilities at its Devens site. This includes a 9,000-square-foot facility expansion with a new process development lab, two additional cGMP suites, and state-of-the-art bioconjugation development and manufacturing capabilities. These initiatives strengthen the site’s highly potent API (HPAPI) and ADC development and manufacturing capabilities. Biosynth has expanded its Berlin facility with a new GMP bioconjugation suite. The expansion supports the company’s manufacturing capabilities in conjugate vaccines, conjugate drugs, activated polyethylene glycol (PEGs), and polymer-based drug delivery excipients. ChemExpress, Mabwell Bioscience, and Insilico Medicine have entered into a strategic partnership to jointly develop a large ADC compound library and advance next-generation ADC candidates. The collaboration combines Mabwell’s antibody and ADC technology, Insilico’s AI-powered drug design platform, and ChemExpress’s expertise in linker-payload chemistry. Together, they aim to build a complete, AI-driven ADC development model that accelerates discovery, optimization, and commercialization. This partnership is expected to enhance R&D efficiency and deliver safer, more effective cancer treatments.  View CDMO Activity Tracker for Q3 2025 (Free Excel Available) Fermion, Axplora, Aenova increase API manufacturing capacities; ICE Pharma expands India facility Finnish CDMO Fermion Oy has launched a renovation project at its Hanko (Finland) production site to modernize its API manufacturing capabilities. This expansion is part of Fermion's broader strategy to increase production, enhance flexibility in the manufacturing of both existing and future pharmaceutical products, and enable potential contract manufacturing opportunities. German CDMO Axplora has announced a €6.5 million (approximately US$ 7.5 million) investment to expand its API manufacturing capacity at its Vizag site in India. This expansion aims to strengthen both production capabilities and supply chain resilience. India-based Aarti Pharmalabs has inaugurated the first phase of its greenfield manufacturing facility in Gujarat (India). This expansion aims to bolster Aarti's CDMO and contract manufacturing organization (CMO) services, targeting a revenue goal of INR 10 billion (approximately US$ 112 million). Snapdragon Chemistry, which was acquired by Cambrex in 2023, has expanded its Massachusetts facility to better support peptide drug development and manufacturing. With this upgrade, the company can now handle peptide projects from early development through full-scale manufacturing. Italy-headquartered ICE Pharma has expanded its Raichem facility in India. The new facility will enhance the production of ursodeoxycholic acid (UDCA), an API it derives from chicken bile. This expansion increases the site’s raw UDCA output by 120 metric tons annually. Spain-headquartered AGC Pharma Chemicals inaugurated a new advanced manufacturing plant in Barcelona, with an investment of €110 million (approximately US$ 128.3 million). The plant spans 7,500 square meters and integrates cutting-edge technologies to support the entire drug development lifecycle — from R&D to commercial manufacturing. This represents a 30 percent increase in the company’s production capacity and introduces a segment dedicated to HPAPIs. Germany-headquartered Aenova has launched a new hot melt extrusion platform at its Regensburg (Germany) site. This new equipment enables the production of advanced drug formulations, while handling all testing and quality checks in-house. The move strengthens Aenova’s capabilities in developing and manufacturing complex medications. US-based Cytovance Biologics has introduced in-house formulation development services, enhancing its role as a comprehensive partner for biologic drug developers. These services utilize quality-by-design principles to ensure speed, safety, and precision in current and future client programs.  View CDMO Activity Tracker for Q3 2025 (Free Excel Available)  Ofichem acquires Avivia BV; Evonik, Samsung Biologics form strategic collaborations Europe-based CDMO Ofichem Group announced the acquisition of Avivia BV, a formulation development company in the Netherlands. This acquisition is part of Ofichem’s strategy to become a fully integrated provider of development solutions across both drug substance and drug product, with a focus on complex formulations. Ofichem has also acquired Meribel Pharma Solutions’ site in Uppsala (Sweden) to strengthen its support for biotech innovators and expand its presence in the Nordic region.  Simtra BioPharma Solutions has acquired a 65-acre property near its Bloomington, Indiana (US) facility, adding over 300,000 square feet of potential expansion space. With this site, Simtra now has the flexibility to rapidly expand in the US. German specialty chemicals company Evonik is partnering with German biotech Ethris to develop and commercialize a next-generation lipid nanoparticle (LNP) platform for delivering nucleic acid therapies. Evonik will assist in formulation using Ethris’ SNaP LNP technology. The LNP market alone is projected to grow to US$2.3 billion by 2032. Luxembourg-headquartered Fareva has partnered with Zhaoke Ophthalmology to expand its footprint in China’s pharma market. Zhaoke will act as Fareva’s go-to partner for customers seeking pharmaceutical manufacturing in China. Samsung Biologics has signed a 1.8 trillion won (US$ 1.3 billion) manufacturing agreement with an undisclosed US-based drugmaker. And UK-based eXmoor Pharma has partnered with Anthony Nolan to provide end-to-end services for cell therapy developers.  View CDMO Activity Tracker for Q3 2025 (Free Excel Available)  Our view The global CDMO market, valued at around US$ 255 billion in 2025, is projected to grow to over US$ 465 billion by 2032. Significantly, about 60 percent of new drug approvals in the US and over 65 percent in Europe now involve CDMO support. The developments outlined above underscore the increasing role CDMOs are playing today in bringing about growth and innovation in the pharmaceutical industry.  
    subscribeSubscribe
    ExcelExcel Download

    Impressions: 401

    https://www.pharmacompass.com/radio-compass-blog/cdmo-activity-tracker-veranova-chemexpress-invest-in-adc-facilities-cohance-to-set-up-oligonucleotide-facility-in-india

    #PharmaFlow by PHARMACOMPASS
    16 Oct 2025
    Share Share

    NEWS #PharmaBuzz

    read-more
    read-more
    European Commission Approves Servier's VORANIGO® (vorasidenib)
    European Commission Approves Servier's VORANIGO® (vorasidenib)

    22 Sep 2025

    // PR NEWSWIRE

    https://www.prnewswire.com/news-releases/european-commission-approves-serviers-voranigo-vorasidenib-as-the-first-targeted-therapy-for-grade-2-idh-mutant-glioma-in-the-eu-302562180.html

    PR NEWSWIRE
    22 Sep 2025
    Share Share
    Servier Acquires Potential Treatment for Fragile X Syndrome
    Servier Acquires Potential Treatment for Fragile X Syndrome

    09 Sep 2025

    // PR NEWSWIRE

    https://www.prnewswire.com/news-releases/servier-acquires-potential-treatment-for-fragile-x-syndrome-the-most-common-genetic-cause-of-autism-spectrum-disorder-302548854.html

    PR NEWSWIRE
    09 Sep 2025
    Share Share
    Servier Commits up To $530 M Into Eye Cancer Deal with Ideaya
    Servier Commits up To $530 M Into Eye Cancer Deal with Ideaya

    03 Sep 2025

    // PRESS RELEASE

    https://ir.ideayabio.com/2025-09-02-Servier-and-IDEAYA-Biosciences-Partner-to-Bring-Darovasertib,-a-Promising-Uveal-Melanoma-Treatment,-to-Patients-Worldwide

    PRESS RELEASE
    03 Sep 2025
    Share Share
    Servier Reports Positive Long-Term Data from Ph 3 TIBSOVO Trial
    Servier Reports Positive Long-Term Data from Ph 3 TIBSOVO Trial

    28 Jul 2025

    // PR NEWSWIRE

    https://www.prnewswire.com/news-releases/servier-announces-positive-data-from-long-term-follow-up-analysis-of-the-phase-3-agile-trial-of-tibsovo-ivosidenib-in-idh1-mutated-acute-myeloid-leukemia-302513961.html

    PR NEWSWIRE
    28 Jul 2025
    Share Share
    Servier Receives Positive CHMP Opinion for Voranigo
    Servier Receives Positive CHMP Opinion for Voranigo

    25 Jul 2025

    // PR NEWSWIRE

    https://www.prnewswire.com/news-releases/servier-receives-positive-chmp-opinion-for-voranigo-vorasidenib-for-the-treatment-of-adults-and-adolescents-with-grade-2-idh-mutant-diffuse-glioma-302513904.html

    PR NEWSWIRE
    25 Jul 2025
    Share Share
    BioMed X & Servier Start AI Antibody Lab In Paris-Saclay
    BioMed X & Servier Start AI Antibody Lab In Paris-Saclay

    09 Jul 2025

    // INDPHARMAPOST

    https://www.indianpharmapost.com/news/biomed-x-and-servier-launch-ai-powered-antibody-research-at-new-xseed-labs-in-paris-saclay-17378

    INDPHARMAPOST
    09 Jul 2025
    Share Share

    USDMF

    read-more
    read-more

    01

    Azepan

    France
    OTS 2025
    Not Confirmed
    arrow

    02

    Butamine Hydrochloride

    France
    OTS 2025
    Not Confirmed
    arrow

    03

    Dexfenfluramine Hydrochloride

    France
    OTS 2025
    Not Confirmed
    arrow

    04

    Indapamide

    France
    OTS 2025
    Not Confirmed
    arrow

    05

    Ivabradine Hydrochloride

    France
    OTS 2025
    Not Confirmed
    arrow

    06

    Perindopril Arginine

    France
    OTS 2025
    Not Confirmed
    arrow

    07

    Perindopril Erbumine

    France
    OTS 2025
    Not Confirmed
    arrow

    08

    Facilities And Operating Procedures ...

    France
    OTS 2025
    Not Confirmed
    arrow

    Facilities And Operating Procedures ...

    France
    arrow
    OTS 2025
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    Servier

    GDUFA

    DMF Review : N/A

    Rev. Date :

    Pay. Date :

    DMF Number : 8576

    Submission : 1990-05-21

    Status : Inactive

    Type : II

    blank

    Product
    Web Link

    Stock Recap
    #PipelineProspector

    Market
    Place

    Full Screen ViewFULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]

    CEP/COS

    read-more
    read-more

    01

    Gliclazide

    CEP/COS

    OTS 2025
    Not Confirmed
    arrow

    02

    Indapamide

    CEP/COS

    OTS 2025
    Not Confirmed
    arrow

    03

    Indapamide

    CEP/COS

    OTS 2025
    Not Confirmed
    arrow

    04

    Perindopril tert-butylamine

    CEP/COS

    OTS 2025
    Not Confirmed
    arrow

    05

    Perindopril tert-butylamine, Laboratorio...

    CEP/COS

    OTS 2025
    Not Confirmed
    arrow

    06

    Rilmenidine dihydrogen phosphate

    CEP/COS

    OTS 2025
    Not Confirmed
    arrow
    Full Screen ViewFULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]

    KDMF

    read-more
    read-more

    01

    agomelatine

    France
    OTS 2025
    Not Confirmed
    arrow

    agomelatine

    France
    arrow
    OTS 2025
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    Servier

    Registrant Name : Korea Servier Co., Ltd.

    Registration Date : 2010-05-27

    Registration Number : Su3056-1-ND

    Manufacturer Name : ORIL Industrie

    Manufacturer Address : 13, rue Auguste Desgenetais, BOLBEC, 76210, France

    blank

    Product
    Web Link

    Stock Recap
    #Pipeline Prospector

    Market
    Place

    02

    Gliclazide

    France
    OTS 2025
    Not Confirmed
    arrow

    Gliclazide

    France
    arrow
    OTS 2025
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    Servier

    Registrant Name : SK Chemical Co., Ltd.

    Registration Date : 2011-08-12

    Registration Number : 20050831-1-C-1-01(1)

    Manufacturer Name : ORIL INDUSTRIE

    Manufacturer Address : Plaine de Baclair, BOLBEC, 76210, France

    blank

    Product
    Web Link

    Stock Recap
    #Pipeline Prospector

    Market
    Place

    03

    Gliclazide

    France
    OTS 2025
    Not Confirmed
    arrow

    Gliclazide

    France
    arrow
    OTS 2025
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    Servier

    Registrant Name : Korea Servier Co., Ltd.

    Registration Date : 2005-08-31

    Registration Number : 20050831-1-C-1-01

    Manufacturer Name : ORIL INDUSTRIE

    Manufacturer Address : Plaine de Baclair, BOLBEC, 76210, France

    blank

    Product
    Web Link

    Stock Recap
    #Pipeline Prospector

    Market
    Place

    04

    Indapamide

    France
    OTS 2025
    Not Confirmed
    arrow

    Indapamide

    France
    arrow
    OTS 2025
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    Servier

    Registrant Name : Korea Servier Co., Ltd.

    Registration Date : 2021-04-05

    Registration Number : 20210405-209-J-922

    Manufacturer Name : ORIL Industrie

    Manufacturer Address : 13, rue Auguste Desgenétais, BP 17, BOLBEC, 76210, France

    blank

    Product
    Web Link

    Stock Recap
    #Pipeline Prospector

    Market
    Place

    05

    Indapamide

    France
    OTS 2025
    Not Confirmed
    arrow

    Indapamide

    France
    arrow
    OTS 2025
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    Servier

    Registrant Name : Youngjin Pharmaceutical Co., Ltd.

    Registration Date : 2021-05-18

    Registration Number : 20210405-209-J-922(1)

    Manufacturer Name : ORIL Industrie

    Manufacturer Address : 13, rue Auguste Desgenétais, BP 17, BOLBEC, 76210, France

    blank

    Product
    Web Link

    Stock Recap
    #Pipeline Prospector

    Market
    Place

    06

    Ivabradine hydrochloride

    France
    OTS 2025
    Not Confirmed
    arrow

    Ivabradine hydrochloride

    France
    arrow
    OTS 2025
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    Servier

    Registrant Name : Korea Servier Co., Ltd.

    Registration Date : 2009-05-28

    Registration Number : 674-1-ND

    Manufacturer Name : ORIL INDUSTIRE

    Manufacturer Address : 13, rue Auguste Desgenetais, BOLBEC, 76210, France

    blank

    Product
    Web Link

    Stock Recap
    #Pipeline Prospector

    Market
    Place

    07

    Perindopril arginine

    France
    OTS 2025
    Not Confirmed
    arrow

    Perindopril arginine

    France
    arrow
    OTS 2025
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    Servier

    Registrant Name : Korea Servier Co., Ltd.

    Registration Date : 2023-05-04

    Registration Number : 20230504-211-J-1487

    Manufacturer Name : ORIL Industrie (Site de Bolbec...

    Manufacturer Address : 13, rue Auguste Desgenétais, BOLBEC, 76210, France

    blank

    Product
    Web Link

    Stock Recap
    #Pipeline Prospector

    Market
    Place

    08

    Perindopril tertiary butylamine

    France
    OTS 2025
    Not Confirmed
    arrow

    Perindopril tertiary butylamine

    France
    arrow
    OTS 2025
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    Servier

    Registrant Name : Korea Servier Co., Ltd.

    Registration Date : 2022-01-03

    Registration Number : 20220103-209-J-1190

    Manufacturer Name : ORIL Industrie

    Manufacturer Address : 13, rue Auguste Desgenétais, BP 17, BOLBEC, 76210, France

    blank

    Product
    Web Link

    Stock Recap
    #Pipeline Prospector

    Market
    Place

    09

    trimetazidine hydrochloride

    France
    OTS 2025
    Not Confirmed
    arrow

    trimetazidine hydrochloride

    France
    arrow
    OTS 2025
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    Servier

    Registrant Name : Korea Servier Co., Ltd.

    Registration Date : 2021-03-16

    Registration Number : 20210316-209-J-878

    Manufacturer Name : ORIL Industrie (Site de Baclai...

    Manufacturer Address : Plaine de Baclair – 76210 BOLBEC, France

    blank

    Product
    Web Link

    Stock Recap
    #Pipeline Prospector

    Market
    Place

    Full Screen ViewFULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]

    NDC API

    read-more
    read-more

    01

    IVABRADINE HYDROCHLORIDE

    France
    OTS 2025
    Not Confirmed
    arrow

    IVABRADINE HYDROCHLORIDE

    France
    arrow
    OTS 2025
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    Servier

    NDC Package Code : 75852-816

    Start Marketing Date : 2014-02-21

    End Marketing Date : 2025-12-31

    Dosage Form (Strength) : POWDER (1kg/kg)

    Marketing Category : BULK INGREDIENT

    blank

    Product
    Web Link

    Stock Recap
    #PipelineProspector

    Market
    Place

    02

    PERINDOPRIL ARGININE

    France
    OTS 2025
    Not Confirmed
    arrow

    PERINDOPRIL ARGININE

    France
    arrow
    OTS 2025
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    Servier

    NDC Package Code : 75852-817

    Start Marketing Date : 2010-09-22

    End Marketing Date : 2025-12-31

    Dosage Form (Strength) : POWDER (1kg/kg)

    Marketing Category : BULK INGREDIENT

    blank

    Product
    Web Link

    Stock Recap
    #PipelineProspector

    Market
    Place

    Only 10 entries up to this point, click to access all click full view read-more
    click full view

    Services

    Upload your portfolio for free, ask us

    Packaging

    Click here to discover the service providers for Packaging

    API Manufacturing

    Click here to discover the service providers for API Manufacturing

    Drug Product Manufacturing

    Click here to discover the service providers for Drug Product Manufacturing

    Analytical

    Click here to discover the service providers for Analytical

    API & Drug Product Development

    Click here to discover the service providers for API & Drug Product Development

    Inspections and registrations

    Upload your audits for free, ask us

    ABOUT THIS PAGE

    Contact Servier and get a quotation

    Servier is a supplier offers 15 products (APIs, Excipients or Intermediates).

    Find a price of Indapamide bulk with CEP, JDMF offered by Servier

    Find a price of Perindopril Erbumine bulk with CEP, JDMF offered by Servier

    Find a price of Gliclazide bulk with CEP, JDMF offered by Servier

    Find a price of Ivabradine Hydrochloride bulk with DMF, JDMF offered by Servier

    Find a price of Captopril bulk with DMF offered by Servier

    Find a price of Hexahydroazepine bulk with DMF offered by Servier

    Find a price of Perindopril Arginine bulk with DMF offered by Servier

    Find a price of Perindopril Erbumine bulk with CEP offered by Servier

    Find a price of Rilmenidine Phosphate bulk with CEP offered by Servier

    Find a price of Trimetazidine Hydrochloride bulk with JDMF offered by Servier

    Find a price of Dexfenfluramine bulk offered by Servier

    Find a price of Indapamide bulk offered by Servier

    Find a price of FACILITIES AND OPERATING PROCEDURES IN BOLBEC, FRANCE bulk offered by Servier

    Find a price of Agomelatine bulk offered by Servier

    Find a price of Gliclazide bulk offered by Servier

    Ask Us for Pharmaceutical Supplier and Partner
    Ask Us, Find A Supplier / Partner
    No Commissions, No Strings Attached, Get Connected for FREE

    What are you looking for?

    How can we help you?

    The request can't be empty

    Please read our Privacy Policy carefully

    You must agree to the privacy policy

    The name can't be empty
    The company can't be empty.
    The email can't be empty Please enter a valid email.
    The mobile can't be empty

    Market Place

    Market Place

    PharmaCompass

    Home

    Market Place

    Menu

    Post Enquiry

    Post Enquiry

    Market Place

    Market Place

    Search